Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 5/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.38 |
| ▸ | MTOR | P42345 | 4/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | DCK | P27707 | 4/20 | 0.35 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.35 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1128369 | 0.89 | PIK3CA (0.49) | PDE9APIK3CAMTORPIK3CGMAPK14 | |
| SCHEMBL4358056 | 0.85 | CYP3A4 (0.49) | PDE9APIN1SLC6A4HRH3CYP3A4 | |
| SCHEMBL4360977 | 0.76 | BTK (0.46) | PDE9APIN1SLC6A4HRH3CYP3A4 | |
| SCHEMBL1128304 | 0.75 | CYP3A4 (0.50) | PDE9APIK3CAMTORPIK3CGATR | |
| SCHEMBL1128370 | 0.75 | CYP3A4 (0.65) | PIK3CAMTORPIK3CGATRAURKB | |
| SCHEMBL1128481 | 0.75 | CYP3A4 (0.50) | PDE9ACYP3A4DCK | |
| SCHEMBL4357229 | 0.74 | CYP3A4 (0.47) | PDE9ACYP3A4 | |
| SCHEMBL4359029 | 0.74 | CYP3A4 (0.47) | PDE9APIK3CAPIK3CGCYP3A4 | |
| SCHEMBL4355613 | 0.73 | CYP3A4 (0.48) | CYP3A4 | |
| SCHEMBL4368392 | 0.71 | CYP3A4 (0.51) | PDE9AHRH3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188098-B2 | GPR119 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286812-A1 | GPR119 Receptor Agonists | GPR119, GPR27, GPR139 | PDE9A 528/4885PIN1 4855/4885PIK3CA 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.